Compare · MXCT vs NRC
MXCT vs NRC
Side-by-side comparison of MaxCyte Inc. (MXCT) and NRC Health (NRC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MXCT and NRC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- NRC is the larger of the two at $563.6M, about 4.6x MXCT ($122.9M).
- NRC has been more active in the news (7 items in the past 4 weeks vs 6 for MXCT).
- MXCT has more recent analyst coverage (11 ratings vs 1 for NRC).
- Company
- MaxCyte Inc.
- NRC Health
- Price
- -
- -
- Market cap
- $122.9M
- $563.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 7
- Recent ratings
- 11
- 1
MaxCyte Inc.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Latest MXCT
- SEC Form 10-Q filed by MaxCyte Inc.
- MaxCyte Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
- MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
- SEC Form SCHEDULE 13D filed by MaxCyte Inc.
- MaxCyte to Participate in Three Upcoming Investor Conferences
- SEC Form 8-K filed by MaxCyte Inc.
- MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
- MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
- MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest NRC
- EVP & Chief Operating Officer Hrdy Helen exercised 12,619 shares at a strike of $18.80 and covered exercise/tax liability with 10,491 shares, increasing direct ownership by 2% to 142,646 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by NRC Health
- SEC Form 10-Q filed by NRC Health
- SEC Form 8-K filed by NRC Health
- NRC Health Announces Third Quarter 2026 Results
- NRC Health Launches nQuire Pro, Extending the Reach of Patient-Experience Teams
- SEC Form 8-K filed by NRC Health
- New NRC Health Research Reveals What Sets High-Performing Health Systems Apart: Turning Patient Feedback Into Action
- The Governance Institute Blue Ribbon Committee Reframes Hospital and Health System Board Assessment with Four Considerations for Stronger Governance
- KLAS First Look: NRC Health Rounding Earns 91.6 Overall Performance Score